C-reactive protein (CRP) is routinely assessed as a marker of systemic inflammation in
rheumatoid arthritis (RA). However, it is also an immune regulator that plays an important …

Physical inactivity is common during periods of self-isolation, but for patients with rheumatic
diseases, there are crucial benefits to be gained from maintaining an active lifestyle …

Objective To evaluate the efficacy, including capacity for inhibition of radiographic
progression, and safety of upadacitinib, a JAK 1‐selective inhibitor, as compared to placebo …

Background Phase 2 studies with upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor,
have shown safety and efficacy in the treatment of patients with active rheumatoid arthritis …

Janus kinase (JAK)/signal transducers and activators of transcription (STATs) are a group of
molecules associated with one of the major pathways through which many cytokines exert …

Patients with rheumatoid arthritis (RA) are at high risk of developing cardiovascular disease
(CVD). Inflammation has a pivotal role in the pathogenesis of CVD. RA is an inflammatory …

Tofacitinib and baricitinib are the first orally available, small-molecule inhibitors of Janus
kinase (JAK) enzymes to be approved for the treatment of RA. Tofacitinib is a selective JAK1 …

Objectives To investigate the effect of Janus kinase inhibitors (Jakinibs) on cardiovascular
risk in adult patients with rheumatoid arthritis (RA) via a meta-analysis of randomised …

The risk of cardiovascular disease is increased in patients with rheumatoid arthritis
compared with the general population owing to the influence of traditional and non …

Baricitinib is an oral, selective inhibitor of Janus kinase (JAK) 1/JAK2 that transiently and
reversibly inhibits many proinflammatory cytokines. This mechanism is a key mediator in a …